Uterine / Endometrial
To find out more about eligibility criteria, click on the ClinicalTrials.gov links and if you are interested in participating, email the coordinator by clicking on the envelope next to the coordinator's name and notify the coordinator.
Treatment stage |
Short name |
Protocol Title |
ClinicalTrials.Gov Link |
Penn Research Coordinator |
Am I Eligible? |
|---|---|---|---|---|---|
| Recurrent | MYTHIC | Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study) | NCT04855656 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | MAGNETIC | Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study) | NCT05147272 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | FAETH | A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) in Subjects with Advanced Solid Tumors with PIK3CA Mutations with or without PTEN loss | NCT05300048 | Katie Elkins |
Enrollment on Hold |
| Recurrent | ATRIN | A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors | NCT04905914 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | TPST-1495 |
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors |
NCT04344795 | Jennifer Louie | Eligibility Criteria |
| Recurrent | Xencor | A Phase 2 Study of XmAb®20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer | NCT05032040 | Isabel Forbes | Eligibility Criteria |
| Recurrent | NP-G2-044-P2-01 | NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | NCT05023486 | Shavon Rochester | Eligibility Criteria |
| Primary Radiation |
GynWPProton |
Whole Pelvis Proton Radiation for Gynecologic Cancer |
NCT05758688 | Kelly Clark | Eligibility Criteria |